cantly lower mean Total scores than controls (54.7 vs. 99.2; PϽ0.0001), Sleep/energy scores (55.9 vs. 100.0; PϽ0.0001), and Bother/concern scores (54.0 vs. 98.3; PϽ0.0001), indicating greater health-related quality of life impairment because of nighttime urination. CONCLUSIONS: The Stanford Sleepiness Scale, Epworth Sleepiness Scale, and N-QoL all effectively discriminate between participants with OAB symptoms and those without OAB symptoms.
OBJECTIVES: Suprapubic catheterization (SPT) is a common urologic procedure performed on an elective and urgent basis. Percutaneous approaches have developed in an effort to circumvent the need for general/spinal anesthesia, but are not without risk. Rates of SPT-related bowel injury range from 0.3% to 2.7%. We experienced 4 cases and reviewed the literature to determine identifiable risk factors for bowel injury. METHODS: A literature review was performed of all English language articles listed in PubMed and articles reporting percutaneous SPT placement related bowel injury were selected. Included in our review are 4 cases in our institution. Data from articles and our cases was extracted to determine the technique of SPT placement utilized, underlying risk factors, and nature of bowel injury. RESULTS: Nineteen papers reported 22 cases of bowel injury as a result of percutaneous SPT placement, 2 of which were excluded for insufficient data. Additionally, the 4 cases at our institution were included in the analysis. Small capacity or thick-walled neurogenic bladders (4/24, 17%), prior abdominal surgery (13/24, 54%), and pelvic radiation (5/24, 21%) were associated with bowel injury during SPT placement. Diagnosis of bowel injury was based on history, physical examination and imaging modalities. Bowel injury had a bimodal presentation, at initial placement (14/24, 58%) and at initial SPT change (10/24, 42%). CONCLUSIONS: Based on this review we advocate consideration of open SPT placement in patients with small capacity or thick-walled neurogenic bladders, those in whom the bladder cannot be distended adequately, prior abdominal/pelvic surgery or radiation, ascites. If percutaneous SPT is planned, Trendelenburg positioning and use of ultrasound and/or fluoroscopy at time of SPT placement is supported by the literature.
PSU2

COMPARISON OF SEIZURE AND HYDROCEPHALUS AND OTHER CLINICAL CONDITIONS BEFORE AND AFTER SUBEPENDYMAL GIANT CELL ASTROCYTOMA SURGERY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
Sun P 1 , Liu Z 2 , Rogerio J 2 , Guo A 2 , Garay C 2 , Kohrman M 3 1 Kailo Research Group, Fishers, IN, USA, 2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3 University of Chicago, Chicago, IL, USA OBJECTIVES: To compare the prevalence rates of seizure, hydrocephalus and other clinical conditions before and after a surgical removal of subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC). METHODS: A pre-post comparative longitudinal cohort study was conducted based on 3 large US national healthcare claims databases (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) . TSC patients with a first observed SEGA surgery at age 35 or younger and with continuous health insurance coverage 1 year before and 1 year after the surgery were selected. The prevalence rates of seizure, hydrocephalus, and other TSC related clinical conditions, such as vision disorders, coma, speechlessness, headache, stroke or hemiparesis, cognitive difficulties, muscle weakness, papillodema, balance disorders, loss of sensation, nausea and vomiting, depression, anxiety, attention deficit disorders, autism, and sleep disorders, were estimated and compared between a period of the last 6 preoperative months and the first two postoperative periods (the 2 nd to 6 th postoperative months; 7 th to 12 th postoperative months). Repeated measures analysis with bootstrapping re-sampling approach was used for the cross-period comparisons. RESULTS: The mean age of the select patients (Nϭ47) was 11.6 year at their first observed SEGA surgery; the majority of the patients were male (66%). Statistically significant postoperative increases in the prevalence rates of seizure (23ϳ 26%, pϽ0.05), hydrocephalus (21ϳ26%, pϽ0.05), headache (17ϳ19%, pϽ0.05), stroke and hemiparesis (6ϳ9%, pϽ0.05), and autism (9%, pϽ0.05) were observed. CONCLUSIONS: This real-world claim data showed an increase in the risk of some clinical conditions including seizure and hydrocephalus after a SEGA surgery in patients with TSC. Further research to explore any possible causal relationship between these risk increases and SEGA surgery through prospective studies or registries is needed. (2000ϳ2009), a retrospective cohort study was conducted in TSC patients who had a SEGA surgery at age 35 or younger, and were under continuous health insurance coverage 1 year before and 1 year after the surgery. A SEGA surgery was identified by a healthcare claim that simultaneously had a TSC diagnosis code, a benign brain tumor diagnosis code and a procedure code of removing a benign tumor from cerebral ventricle system. The surgical complications examined in the study included surgical procedure complications, nervous system complications, surgical misadventures, postoperative infection, subdural empyemas, and epidural abscess. The prevalence rates of these conditions were estimated for the first postoperative year. RESULTS: Approximately 47 TSC patients had at least one SEGA surgery. The mean age of patients at their 1 st observed SEGA surgery was 11.6 years. The majority of patients (66%) were male. The prevalence rates of surgical complications in the 1 st postoperative year were 34% for surgical procedure complications, 17% for subdural empyemas, 12.8% for nervous system complications, 6% for postoperative infection, 2% for epidural abscess, and 0% for surgical misadventures respectively. CONCLUSIONS: In this real-world claim database analysis, we observed that a portion of TSC patients experienced surgical complications within first year after their SEGA surgeries. Further research is needed to better understand the causes of this surgical outcome.
PSU3 PREVALENCE RATES OF SURGICAL COMPLICATIONS AMONG TUBEROUS SCLEROSIS COMPLEX PATIENTS WITH SURGICAL REMOVAL OF SUBEPENDYMAL GIANT CELL ASTROCYTOMA: A REAL-WORLD NATIONAL RETROSPECTIVE COHORT STUDY
PSU4 POSTOPERATIVE PREVALENCE RATE OF SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) DIAGNOSIS AND REPEATED SEGA SURGERY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX: A REAL-WORLD NATIONAL RETROSPECTIVE COHORT STUDY
Sun P 1 , Liu Z 2 , Rogerio J 2 , Guo A 2 , Garay C 2 , Kohrman M 3 1 Kailo Research Group, Fishers, IN, USA, 2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3 University of Chicago, Chicago, IL, USA OBJECTIVES: To examine the postoperative prevalence of subependymal giant cell astrocytoma (SEGA) diagnosis and repeated SEGA surgeries among patients with tuberous sclerosis complex (TSC) who had an initial SEGA surgery. METHODS: Based on three US national health claims databases (2000ϳ2009), we conducted a retrospective cohort study with TSC patients who had a first observed SEGA surgery at age 35 or younger and were under continuous health insurance coverage 1 year before and 1 year after their 1 st SEGA surgery. A SEGA surgery was defined as having 1) a TSC diagnosis code, 2) a benign brain tumor diagnosis code, and 3) a procedure code for removing a benign tumor from cerebral ventricle system. A SEGA diagnosis is defined as 1) and 2). The prevalence rates of postoperative SEGA diagnosis and repeated SEGA surgery were estimated for a period from the 3 rd through 6 th postoperative month and a period from the 7 th through 12 th postoperative month respectively. RESULTS: The select patients (Nϭ47) had mean age of 11.6 years (at the 1 st SEGA surgery) with 66% males. After the 1 st observed SEGA surgery, postoperative prevalence rates of SEGA diagnosis was 34% in the period from the 3 rd to 6 th postoperative month and 26% in the period from the 7 th to 12 th postoperative month. About 4ϳ9% patients had a repeated SEGA surgery in their 1 st postoperative year. CONCLUSIONS: In the real-world setting, TSC patients with SEGA surgery may experience repeated SEGA surgeries or/and still have SEGA diagnoses within the first postoperative year. Further research on the effectiveness of SEGA surgery via prospective studies or registries is needed to improve care in TSC patients with SEGA.
